EGFR and colorectal carcinoma: Thus, the activation of KRAS mutation is used as a negative indicator for a lack of answer to anti‐EGFR treating.[3, 4] While WT KRAS tumours are indicated for adoption of anti‐EGFR treatment, not all patients will respond,[5] so predictive features are required for insights into the response and resistance to EGFR‐targeted therapy in CRC.